2025-03-31-accounts

Company registration number.. 10089069 Charity registration number.. 1186416 Hannah's Willberry Wonder Pony Charity IA company limited by guaranleel Annual Raport and Financial Statements for the Year Ended 31 March 2025

Hannah's Willberry Wonder Pony Charity Contents Trustees, Ret)ort 1to22 Reference and Adminislralive Details 21 Indèpendent Examinerfs Report 23to24 Statement of Financial Activities 25 8alance Sheet 26 statement of Cash Flows 27 Noles to the Financial Slalemenls 281035

Hannah's Willberry Wonder Pony Charity Trustees, Report The Iruslees. who are directors for the purposes of company law, present the annual report together with the financial slalemenls and auditors. report of the charitable company for the year ended 31 March 2025. Objectives and activities Our purpose Hannah's Willbèrry Wonder Pony Charity seeks lo provide 8 public benefit by. promoting research into the causes. prevention and Irealmenl of bone cancer and other types of cancer., promoting the health and wellbeing of people with a disability or serious illness.. or. people who are affected by the disability or serious Illness of a close family member,. OT, people who are sufferirig from bereavement following the death of a close family mernber, by providing or assisting in the provision of opportunities lo ride or enjoy other equestrian related experiences., and assisting in the Irealrllenl and care of people suffering from bone cancer and other types of cancer and lo help people caring for them. The Charity can provide.. grants lo organisalions carwng out research into bone cancer, provided that the results of the research funded will be published. In the event that the Charity is not the sole funder of any research then the grant of funding wll be subject lo a condition that results of research will be published and available for general use., grants lo organisations, individuals and their families to assist those affected by bone cancer and other types of cancer.. an experience of an equestrian nature via our Willberry's Wishes team, making precious mem0ri8S to treasure forever. Background Hannah Francis founded the charity, Hannah's Willberry Wonder Pony, in March 2016, having been diagnosed with osteosarcoma the year before at just 17 years old. She wanted lo leave a legacy and help people likg her who are affected by a serious illness and wanted the Charity lo raise money lo fulfil Mo principal objectives.. lo fund research into osteosarcoma I'willberry's Research),. and lo provide equestrian experiences lo seriously ill people and Ihoir families I Willberry's Wishes'l. Th8 Charity went from strength lo strength under Hannah's leadership and has continued lo grow since her passing in August 2016, raising more than £2 million lo dale. The Charity has funded a number of significant research projects as Hannah so dearly wished," she fought so courageously and endured such archaic Irealmenl that she never wanted anyone else lo have lo go through this. Hannah lived for her horses and whilst she was ill, she licked many equine dreams off her bucket list, and this gave her the inspiration for 'Willberry's Wishes". The Charity is granting Willber￿S Wishes lo seriously ill people in the hope that these experiences inspire others in the same way as they did Hannah, bringing a little happiness and hope during the darkest of limes. P8g8 1

Hannah's Willberry Wonder Pony Charity Trustees, Report We the Trustees are grateful lo the thousands of people who have helped with donations, fundraising and spreading the word about Hannah's Willberry Wonder Pony Charity. When necessary, the Charity engages the services of experts lo assist with the running of the Charity bul for the vast majority of the lime il has been run by volunleers, including the Trustees, and we are very proud of everyone's efforts in keeping the cost of running the Charity to a minimum and thus ensuring maximum funds are available lo apply lo public benefit. However. the need for full lime staff has been continually under review lo ensure th8 Charity continues to run efficiently and maximises ils public benefit and some changes in this respect have been made from 1 March 2025 and are reported In detail on page 19. That said, we ar& especially grateful lo our volunteers for the financial protection they give us by giving many hours of their lime, as well as opening their homes for meetings and providing storage space for our trading subsidiary's merchandise stock. Our Activities During 2024125 and Achievements lo Date We believe that the Charity has provided a public benefit in the following ways.. In our ninth full year as a charity w8 have raised funds of £79,050 (previous year £83,630) on income of £155,090 Iprevious year £156,509). This was another successful year in terms of funds generation, with fundraising efforts delivering good growth in income. We are incredibly grateful for the fabulous fundraising efforts and donations from so many of our supporters. We also received generous donations from individuals, trusts and other charities. The money raised will help to provide funds lo meet the Charity's objectives and provide PLJblic benefit in the years lo come by helping fund bone cancer research and providing Willberry's Wishes. The trading subsidiary, which sells Willberry branded merchandise and donates all ils profits lo the Charity 1£18.116 in 2024125, previous year £24,438), has had another successful year. Demand remained steady for our Berry Ponies and for other items which were also sold al 8questrian events including Badminton Horse Trials, where some riders still lake lo the cross-counlry Course with their berry pony slrapped lo their backs. thus giving the Charity continued and valuable public profile. The portfolio of branded items offered Is constantly reviewed to ensure that we keep our followers happy and achieve the best f1nancial outcome. Page 2

Hannah's Willberry Wonder Pony Charity Trustees, Report During the year, we have provided a number of Willberry's Wishes to people who are fighting, or are affected by, serious illness. Spending during the year providing these experiences amounted lo £4,485 which included.. A lady was very poody with breast cancer and her pony of 25 years sadly died. she wanted a portrait of her pony. We arranged for an artist lo painl ihis, the lady was over joyed with the beautiful portrait of her beloved pony. A little girl with a terminal brain tumour wanted lo have a pony party al home with her friends and family. We arranged for some ponies lo go to her house, the morning was packed full of pony rides and pony pampering. A special pony cake was delivered and everyone received a special roselle. The little girl could not believe that she had ponies in her own back gardenl A lovely lady came and look photos which we then created a photo album for the family, memories for everyone. A special girl who had ballled cancer went lo Badminton, where she had a lovely time. We also arranged for her lo have a special VIP visit lo the Badminton stables With a guided lour from Kitty King. She met many of the competitors and their famous horses. We helped another special girl with a terminal diagnosis. She owned a sprilely horse called Patrick, full of energy rnaking him a little loo much for her lo ride as she was so poorly. She adored her horse, so we wanted lo include him in her wish, so we organised a photo shoot with her horse and family. A beautiful sunny day in Cornwall. creating some exquisite photos that we made into a book, making memories forever. For a tiny team, we created the largest wish a pony party for the entire class, 38 children. A little gid with osteosarcoma who had missed so much school as she was in and out of hospital. She missed her friends and wanted lo include them in her'willberry's Wish.. so we travelled lo Cornwall lo hold a 'Pony Party. at her school. We arranged for a local riding school lo join us,. they brought some ponies and organised the rides for all the children. We split the class into four groups and they rolaled around the aclivilies, riding, dismounted gymkhana games, face painting, pin the tail on the donkey and decorating Willberry biscuits, a very busy afternoonl Then back to the classroom for a picnic, and lo see the special cake we had made. Willberry had even brought party bags for all the children. We are extremely fortunate that many wonderful people in the equestrian community assist us in providing Wishes al no charge lo the Charity. Since formation, many Wishes have been granted and all of these have been very well received by the re¢ipienls. although understandably not all permit publicity We look fotward lo providing many more. In respect of medical research, we have in place an expert panel to assist the Trustees in selecting and analysing bone cancer research projects. The expert panel is headed by Dr Claire Clarkin. Associate Professor of Developmental Biology, University of Southampton, and she is very ably assisted by Dr Alice Goring, who completed a Pho related lo the study of the role of blood vessels in bone diseases, and they both provide critical assistance lo the Charity in managing the medical research investment process. We have continued lo meet a number of clinical and academic specialists in Ihe field of osteosarcoma research and have made significant progress in increasing the prof11È of the Charity in the academic and scientific communities, including advertising for PhD sludenlships with major universities. Page 3

Hannah's Willberry Wonder Pony Charity Trustees, Report In lolal lo dale, we have identified and committed lo twelve research projects from leading English Universities that we are supporting, with a combined value of up lo £1,155,480, of which £45,316 was spent in the financial year. We are confident that in the coming year5 we will identify projects from other inslilulions that will assist in the idenlificalion of the causes, prevention and Irealmenl of bone cancer and other types of cancer. These efforts will be significantly enhanced by last year's announcement that the Charity will be working together with The Bone Cancer Research Tru511o offer funding of up lo £250,0001£125.000 funded by each charilyl to sUPPOrt projects focused on improving outcomes for osteosarcoma patients. The lead lime for identifying, reviewing. approving and funding research projects remains up lo 2 years. The Trustees are very conscious of the need lo select prospective research projects ¢arefLJIIy and lo ensure the Charity's money is invested in a considered and appropriate way. Our Strategy Going Forwards The Trustees continue lo review the strategy of the Charity lo ensure that It provides public benefit and has the ability lo meet ils objectives. The Trustees are hopeful that income generated in 2025126 will meet our largel of £100,000 and this, together with our strong reserves, will enable us lo carry out the Charity's objectives in future years. FUNDING RESEARCH PROJECTS As mentioned above, the Charity has entered into agreements to fund twelve research projects since the charity's inception. 11 remains shocking lo note that chemotherapy treatment for osteosarcoma has changed little in the past 30 years and has a limited success rate. The Irealmenl is barbaric and causes suffering and horrific side effects. New ways lo fight this devastating disease are urgently needed. The projects that we have funded. or are Currently funding, are listed below.. COMPLETED RESEARCH PROJECTS The first is a fully funded post doctoral position and a part funded PhD student with th8 Tenowned Department of Oncology and Melabolisrn at Sheffield University with a lolal cost of £233,412. The project ran from 2019 to 2023 and can be summarised as follows.. Project Tltle.. Can we Identlfy new drugs for the treatment of osteosarcoma? and flndlng out why exlstlng ones don't WOTk Key people.. Professor Ali Gartland, Professor Dominique Heymann and Luke Tattersall and Victoria Tippett. Page 4

Hannah's Willberry Wonder Pony Charity Trustees, Report BACKGROUND TO THE RESEARCH PROJECT Osteosarcoma is the most common type of primary bone cancer affecting children and adolescents. il is a rare and often fatal disease. Historically, the over8115-year surviva1 rates for osteosarcoma were dire al below 200/0 with surgical intervention alone. The introduction ol the addition of chemotherapy treatment after surgery in the 1970s radically increased rates lo 500/.. Since then, and the introduction of chemotherapy before SLJrggry, the survival rate further increased lo 600/.. However, there has been no real advances in Irealmenl options and the survival rates have remained poor. The 5-year survival rale is reported lo be 53 /0 for patients under 40, versus 22 0/. for those above. The rale is even worse for patients who present with metaslalic disease al less than 300/D and this has actually declined every decade, with no significant change in the survival when comparing the 21 sl Century figures lo those from the 1970s. Current Irealmenls for osteosarcoma are also brutal and rely on classical chemotherapy drugs which have significant side effects due lo the fael that they also kill non-cancerous cells and patients often become resislanl lo the therapy, meaning that they no longer work and further limiting their Irealmenl options. This project aimed lo find new kinder drugs that will work in osteosarcoma. even when they become resistant lo the first line therapy. KEY RESULTS The Gartland lab has lesled 4320 compounds from a "drug library . which includes many drugs and natural compounds that have already been shown lo be harmless in people, for their effect al reducing the growth of osteosarcoma cells. Their extensive investigations using osleosarcoma cell lines in the laboratory have identified 5 COrnPOLJnds that are highly polenl requiring low doses lo redLJce osteosarcoma cg11 growth. Thesg drugs also reduced the ability of the osteosarcoma Cells lo move suggesting Ihoy may be able lo prevent osteosarcoma spreading Imelaslasisingl lo other parts of the body. The team also lesled these drugs against osteosarcoma cells that they had made resislanl lo conventional doxorubicin chemotherapy and they were able lo kill these ￿11$ loo. In addition lo these findings specifically in osteosarcoma, these drugs have been shown to have effects in other cancers. They are now trying to get more gvidence that these new drugs work so we can take them fonNard lo being used in patients. The Gartland lab also used the chemoresislanl cells they developed lo investigate the way in which the osteosarcoma cells stop responding lo the first line chemotherapy. Excitingly they have found new signalling pathways and potential drug largels that are involved in the cells becoming chemoresistsnl and now wanl lo investigate these further as potential new treatment oplions lor osteosarcoma. Other oulpuls. knowledge and Future Steps Publications.. The Gartlarid lab is currently refraining from publishing the full results from the studies of Dr Luke Tattersall until successful IP has been filed for., proleeling the drug compounds. and increasing translatabilily into patients. The lab Is trying lo further validate the hits from the screening to get the pre-clinical evidence to lake the hits forward lo clinical use in patients. They are also trying lo modify the drugs lo target them specifically to bone and so reduce any potential side ettects. Page 5

Hannah's Willberry Wonder Pony Charity Trustees, Report V.L. Tippett, L. Tattersall, K.M. Shah, Ab Lalrf, N.8, M.A. Lawson, A. Gartland. "The strategy and clinical relevance of in vilro models of MAP resistance in osteosar¢oma.' a syslemalic review. Oncogene 2022 Presentations.. Or81 Presentation al the first HWINPC research syrnposium. London, UK, "Can we find new effective Irealmenls lor osleosarcoma?. L. Tattersall, V.L Tippett, A. Higginbottom, A.Gartland Poster Presentation at the Bone Research Society Annual Meeting, Liverpool, UK, 'Eslablishment and characterisalion of a human osteosarcoma mela5tatic cell line derived from a patient's lung for future preclinic81 use L. Taitersall. V.L Tippett. J.K. Ranlala. A. Higginbollom, A.Gartland. Snap Oral Presentation al th8 12th Annual Mellanby Centre Research day, Sheffield UK. "Eslablishmenl and characlerisalion of a hurnan osteosarcoma melaslalic cell line derived from a patient's lung for future preclinical use" L. Tattersall, V.L Tippett, J.K. Ranlala, A. Higginbottom. A.Gartland. Oral Presentation at the first PRESTO meeting, Ferrara, Italy. "The P2RX7B splice variant modulates osteosarcoma cell behaviour and melasialic properties" L. Tallersall. K.M. Shah, D.L. Lalh, A. Singh, J.M. Down, E. De Marchi, A.Williamson, F.Di.Virgilio, D. Heymann, E.Adinolfi, W.D. Fraser, D. Green, M.A. Lawson A.Gartland. Oral Presentation al the Bone Cancer Research Trust Annual Confer8nce INorthl Leeds UK. "Can we find new effective treatments for osteosarcoma?" L. Tattersall. V.L Tippett. A. Higginbottom. A.G8rtland Snap Oral Presentation at the 11th Annual Mellanby Centre Research day, Sheffield UK, "Can we find new effective treatments for osteosarcoma?" L. Tattersall, V.L Tippett, A. Higginbollom, A.Gartland Poster Presentation al the BSG annLJal conference Liverpool UK, "Can we find new effective Irealmenls for osteosarcoma? L. Tattersall, V.L Tippett. A. Higginbottom, A.Gartland Oral Presentation al Ihe 10 year UK Purine club anniversary conference, Sheffield UK, P2X7RB Increases ectopic bone disease and lung melaslasis in vivo L. Tallersall. K.M. Shah, D. Lath, J. Down, E. De Marchi. A. Williamson, F. Di Virgilio, E. Adinolfi, M.A. Lawson, A. Gartland. Oral Presentation at the 9th Annual Mellanby Centre Reséarch day, Sheffield UK, Effects of P2X7RB expression on MNNG-HOS osl&osarcoma ¢ells in vitro L. Tattersall, E. De Marchi. A. Williamson, F. Di Virgilio, M.A. Lawson, E. Adinolfi, A. Gartland Poster Presentation al the BACR lumour microenvironmenl meeting, Nottingham UK P2X7RB increases ectopic bone disease and lung melaslasis in vivo in osteosarcoma Tatters811. L, Down. J, Lalh. D, De Marchi. E, Williamson. A, Di Virgilio. F, Adinolf1. E, Lawson. M.A. Gartland. The Charity has also part-fundèd a PhD student al the University of Manchester with a total cost of £51,057. Page 6

Hannah's Willberry Wonder Pony Charity Trustees, Report Project Title: Understandlng how ERK5 controls osteosarcoma development and response to treatment. Key people.. Professor Katie Finggan, Kaye Williams, Adam Mcmahon. Alex Dzhongva BACKGROUND TO THE RESEARCH PROJECT There is evidencg from currenl rosearch work undertaken in this lab that a protein called ERK5 can promolo the progrgssion of osteosarcoma. Clinical studies have also revealed a strong link between ERK5 signalling and Dutcomes for osteosarcoma patients. A recent study of samples from osteosarcoma patients showed that high levels of ERK5 correlated with disease progression187'/0 of palienlsl, resistance to chemotherapy 153 /0 of palienlsl, and was detected in 70°/0 of metastases, wherg it ¢0￿e1a1ed with decreased overall survival. ERK5 is a protein and sends many messages lo other proteins, which then tell the cell what lo do. Cells responding lo the signal are not only lumour cells, but also cells that belong lo the bodys immune system, which in cancer, are hijacked lo aid cancer progression. The team have initial evidence that removing ERK5 inlerrupls the signals or "conversation" between the immune cells and the lumour cells. A lumour cells "conversation. with the immune system is essential for both tumour growth and spread lo other parts of the body. When genetic approaches lo remove ERK5 from osteosarcoma cells growing in mice are used, this slops spread of the osteosarcoma cells lo the lung. However. although il is known that eliminating ERK5 from the cells has significant impact Dn osleosar¢oma progression. il is not known exactly how this happens. Understanding the "how" is pivotal lo understanding the best way lo target this pathway and inform design of drugs acty'ng against ERK5 signalling for future patient use. KEY RESULTS Blocking ERK5 either by the Finegan lab's genetic approach or by their new patented drug slops osteosarcoma cells from being able to spread. Blocking ERK5 Idruglgenetic approach) enabled the lab lo use a lower dose of chemotherapy lo gel the same effect. This means, in the future, the drug could be used to low8r chemotherapy doses and therefofe enable kinder Irealmenl plans for patienls. Blocking ERK5 Idruglgenetic approachl is a possible new immunotherapy for osteosarcoma. The Finegan lab found that their drug can make the immune system more able lo attack osteosarcoma tumours and also that il may be able to make current on-the-shelf immunotherapy more effectiv8. The Finegan lab analysed patient tumour samples and this suggested that we can use ERKS levels in patient samples as a way to identify patients that rnighl be at higher risk of their cancer spreading. They have also found that most osteosarcoma patients lumours 1-80/01, but especially those patients lumours whose osteosarcoma had spread or had gone on lo spread, had high ERK5 in them. Due to having lols ol ERK5, these 80.10 of osteosarcoma patients would be very likely lo benefit from our drugs that block ERK5. Page 7

Hannah's Willberry Wonder Pony Charity Trustees, Report Outputs This project has allowed the lab lo secure onward funding from Sarcoma UK and LifeARc lo progress their drugs further towards use in patients and to develop their work on ERK5 levels in patient lumours. This means that they can use this clinically lo identify high risk patients early on and therefore offer the best opportunities for Irealrnenl. The charity has also fLJnded two part-funded PhD projects al the University of Soulhamplon, with a combined funding of £102,449 over 3 years each between 2019 and 2023. First Project Title: Developlng a 3-dimensional multicellular model of human osteosarcoma Key People.. Dr Janos Kanzler, Professor Steve Beers, Professor Juliet Gray, Hannah Smith BACKGROUND TO THE RESEARCH PROJECT The most common bone cancer in young people is osteosarcoma. It is an aggressive cancer and unfortunately Irealment hasn't progressed mLJch in 40 yoars. This team al Southampton have created a laboratory model of ost8osarcoma lo try and better understand how this disease arises from nomial bone cells and lo lesl polential new therapies lo prevent Ihe growth of this canc8r. The origin of osteosarcoma colls in bone is still unknown. and this lack of understanding prevents earty detection of this disease. Bone grows from specialised cells located in the bone marrow Ilhe soft, jelly-like tissue found in the Centre of most bones). In Hannah's PhD project, the team were interested to see if thare were differences behveen the cglls of the bone marrow from dislincl locations of the long thigh bone and whether those differences might impact their ability lo initiate disease. To do this, they coll8clgd and grew these specialised bone marrow cells from different rggions of human bones (these were called red and yellow bone marrow) wher8 osteosarcoma cancers lend lo develop. They then looked al the ability of these Cells lo change into three types of cells. osteoblasts which make bone, adipocytes which make fal and chondrocytes which make cartilage, all ol which are critical in shaping, growing, and repairing our skelglon particularly al a youthful age. The team compared the characteristics of these cells wilh two known osteosarcoma cells lcalled Saos-2 and MG631. From Hannah's studies, she found that bone marrow specialised cells changed differently when slimulaled depending on the region of the bone they came from. Improved understanding of the origin and the bone environment where these osteosarcoma cells develop could allow for eartier detection and treatment of the disease to improve the patients overall outcome. KEY RESULTS Why and how osteosareoma cells start growing is still unknown. and this laek of understanding prevents earfy detection of this disease. Bone grows from specialised cells located in the bone marrow (The soft, jelly-like tissue found in the centre of most bones). During Hannah's PhD, the team was interested lo see if there were differences between the bone marrow cells from dislincl locations of the femur which might impact their ability lo initiate disease. They collected and grew these specialised bone marrow cells from two diffgrgnl regions (called rgd and yellow bone marrow) and found that there were big differences in how they changed into cells which make bone, fal, and cartilage. Page 8

Hannah's Willberry Wonder Pony Charity Trustees, Report They also looked al two types of osteosarcoma cancer cells and how similar they were to the bone marrow ce115, Wlth one called Saos-2 showing a similar ability to form bone like the bone marrow cells. After incub81ing the bone cylinders they were successfully able to look at whether there was bone growth or loss, as well as changes in their fealure511r8ils. They identified that the cells stayed alive and were interacting in this model lo recreate the human lumour. Finally, the drug rnrfamurtide was lesled on the bone model, and it was found that it resulted in lower bone volume and changes in the model's characlerislics, which will help in understanding why not all patients respond lo mifamurtide. Other outputs, knowledge and Future Steps Publications.. 'Smilh, H. L., Beers, S. A., Kanczler, J. M.. & Gray, J. C. Developing a 3D model of osteosarcoma to investigate cancer mechanisms and evaluate Irealments. Submitted for publication Dec 2023 and under revision. 'Smilh, H. L., Gray, J. C.. Beers, S. A., & Kanczler, J. M. 120231. Tri-Lineage Differenlialion Potential of Osteosarcoma Cell Lines and Human Bone Marrow Slromal Cells from Different Anatomical Loca110115. Inl J Mol Sci. 24141. https'.Ildoi.org110.33901ijms24043667 'Smilh, H. L., Beers. S. A.. Gray, J. C., & Kanczler, J. M. 120201. The Role of Pre-clinical 3-Dimensional Models of Osteosarcoma. Int J Mol Sci. 211151. https'.Ildoi.org110.33901ijms21155499 'Smilh, H. L., Kanczler. J. M., Gray, J. C.. & Beers, S. A. Monocyte Derived Macrophage5.' Peripheral Blood vs Bone Marrow. In final preparation for submission. Estirnaled End of Feb 2024. Presentations-. 2023 - Hannah's Willbery Wonder Pony Charity Symposium - Oral presentation 2022 - Centre for Human Developrnent, Stem Cells and Regeneration conference Oral presentation 2020 - Bone Research Society.. Osteosarcoma cells modulate skeletal strornal cell phenotype- sile specific interactions. Poster presenlaty'on 2020 - Cancer Research Club -oral Presentation 2019 - 11 th Annual Cancer Sciencgs Unil Conference- Poster Presentation Pagg 9

Hannah's Willberry Wonder Pony Charity Trustees, Report Second Project Title.. Harnessing Label-Free. Second Harmonic Generation Microscopy for Research and Diagnosis of Osteosarcoma Key people.. Belle Creilh, Dr Claire Clarkin, Professor Sumeet Mahajan, Professor Richard Oreffo and University of Southampton gACKGROUND TO THE RESEARCH PROJECT This research project aims to introduce a new technology for the diagnosis and examination of osteosarcoma lumours. Current diagnosis of osteosarcoma is a very time-consuming process involving a number of imaging techniques and a confirmalive biopsy. Cutting-edge laser microscopes that allow the imaging of biological samples in 8 non-invasive mannèr are being widely explored in the field of cancer research as they do not require the use of any special dyes of labels. This research pr(ijecl ulilises one such laser microscope known as second ham)onic generation microscopy - being used as a new method for the diagnosis of osteosarcoma by examining abnormal collagen - a protain in our bones which is thought lo be changed drastically within tx)ne lumours. KEY RESULTS During this research project, the team developed an optimised imaging and analysis methodology that allowed accurate examination of Collagen in hLJman bone and osteosarcoma biopsies. Their findings provide proof-of-concepl for osteosarcoma diagnosis by idenlify'ng abnormally short collagen fibres within osteosarcoma lumours compared lo healthy bone. They also identified that these changes lo Collagen length become more pronounced with progression of osteosarcoma. Furtherrnore. the Southampton team discovered that the collagen of osteosarcoma lumours also shows some differences from the collagen in other bone Cancers. Together, these results demonstrate the diagnostic ability of SHG microswpes by idgnlifying diseased collagen. This could help with both diagnosis of the disease as well as prediction of osteosarcoma progression and response lo Irealmenl. Moreover, their findings also highlight diseased collagen as a biological molecule that may be largeled in future osteosarcoma Irealmenl. Other Oulpuls & Knowledge and Future Steps Creith B, Johnson PB, Harrison J. Oreffo ROC, Mahajan S and Clarkin CE 120211. Prospects of multi-modal non-linear microscopy for research and diagnosis of osteosarcoma. Accepted for oral presentation. Bone Research Society Annual Meeting (virtual program), 28-30 June. Creith 8, Johnson PB. Harrison J. Oreffo ROC. Mahajan S and Clarkin CE120221. Charactefisalion of Diagnostic Collagen Phenotypes in Human Osteosarcoma 8iopsies Using Second Hamonic Generation Imaging. Accepted for poster presentation. Bone Research Society Annual Meeting, Manchester, 64 July. Creilh B. Johnson PB, Harrison J, Oreffo ROC. Mahajan S and Clarkin CE 120221. Diselosing Diagnostic Collagen Phenotypes in Osteosarcoma Biopsies with Second Harmonic Generation Imaging Accepted for oral presentation. Gordon Research Seminar on Musculoskeletal Biological and Bioengineering, New Hampshire, USA, 6-7 August. Page 10

Hannah's Willberry Wonder Pony Charity Trustees, Report Creith B. Johnson PB, Harrison J, Oreffo ROC, Mahajan S and Clarkin CE 120221. Disclosing Diagnostic Collagen Phenotypes in Osteosarcoma Biopsies with Second Harmonic Generation Imaging. Ac¢epled lor poster presentation. Goidon Research Conference on Musculoskeletal Biological and Bioengineering, New Hampshire. USA, 7-12 August. Creilh B, Johnson PB, Harrison J, Oreffo ROC, Mahajan S and Clarkin CE 120221. Prospects of Label-Free Microscopy for Research and Diagnosis of Osteosarcoma. Invited for Talk. North Bone Cancer Research Trust Conference. Leeds. UK. 14-15 October. Future steps.. In parallel with our PhD funding Southampton was successful in obtaining further funding from Children with Cancer UK in collaboration with Janos Kanczler. University of Soulhamplon on a project enlilled Developing 3-dimensional multicellular models of osteosarcoma which was undertaken by Dr Aikta Sharma Backsround '. OS has been shown lo be very sensitive lo its surroundings and particularly that of circulating immune cells called rnacrophages. Macrophages protect the body by locating and "eating" particles, such as cancer cells, bacteria. viruses, fungi, and parasites. The presence Df macrophages in OS has been reported lo be assoeialed with increased patient survival and has led to a largeled drug Irealmenl called mifamurtide, a rllacrophage aclivalor. However. recent evidence has questioned the benefit of this treatment approach in all patients. We urgently need lo understand the microenvironmenl of OS and investigate how these macrophages can influence the clinical outcome of young OS patients. In this project, Dr Claire Clarkin and her team will develop a live 3D multicellular model of OS by combining human bone pieces, OS cells and immune cells, which will be kept alive and grown together inside a developing chicken egg. This sophislicaled model of OS will better replicate the complex lumour microenvironmenl than existing models and will be used lo assess the mechanisms underlying specific drugs. like mifamurtide, in killing OS ¢ells. The research team will then use a powerful imaging technique called Raman Spectroscopy lo identify any unique disease signatures. Idenlificalion of such signatures could act as an indicator for OS lo improve diagnosis and will provide greater understanding into the role of immune cells in the progression of OS. This study will assess the polonlial for macrophage activation lo be used in the Irealmenl of OS and will allow drugs lo be screened very rapidly to assess their effectiveness. The research team will identify and characlerise unique OS cell signatures which could be used as indicators for the disease and could impfove the speed of diagnosis. Findings have demonslraled the utility of Raman spectroscopy in the characlerisalion Df matrix signatures of osteosarcoma. The team have performed In-depth in vilro characlerisalion ol low-to-high grade human osteosarcoma cell lines and validated the attained spectral signatures with biochemical assays which have enabled the deduction of cellular metaslalic and differentiation capacities directly from exlracellular matrix signatures. The project team's approaches can be used a platfom) for rapid screening of novel therapies for osteosarcoma Irealmenls ahead of adminislralion lo larger preclinical models. The Clarkin lab's future funding strategy will ulilise the methodologies developed herein lo form the basis of a larger grant applic81ion (Medical Research Council, Cancer Research UK, Bone Cancer Research Trust) with locus on improving osteosarcoma diagnosis and treatment using multidisciplinary approaches. Outputs.. Homsey T, Sharma A, Michels L, Kerns J , Clarkin CE 120241. Machine Learning predicts unique exlracellular matrix characlerislics between osteosarcoma cell phenotypes. Submitted for oral and poster presentation al the European Calcified Tissue Congress, Marseille, France. May 2024. Page11

Hannah's Willberry Wonder Pony Charity Trustees, Report Sharma A, Oreffo ROC, Mahajan S, Beers S. Kanczler J and Clarkin CE120241. Raman spectroscopy reveals the association be￿een nanomolecular matrix signatures with pro-angiogenic polenli81 in osteosarcoma. Accepted for poster presentation al the Bone Cancer Research Trust Meeting: Advancing diagnosis of bone and soft115sue sarcomas, Loeds, UK, January 2024. Sharma A, Oreffo ROC, Mahajan S. Beers S. Kanczler J and Clarkin CE 120231. Characlefisalion of osteosarcoma matrix signaturas reveals nanoscale molecular composition is linked lo pro-angiogenic potential. Accepted for oral and poster presentation al the Bone Research Society Annual Meeting and European Calryfied Tissue Society Congress 2023, Liverpool, UK, April 2023. Sharma A, Oreffo ROC, Mahajan S, Beers S, Kanczler J & Clarkin CE 120221. Nanoscale characlerisation of osteosarcoma cell matrix signatures link lo pro-angiogenic polenlial. Accepted for poster presentation al the Gordon Research Seminar and Conference on Musculoskeletal Biology and Bioengineering.. Mulli-scale Approaches to Understanding Musculoskeletal Tissues, New Hampshire, USA, August 2022. The Charity has also part-funded ￿ PhD projects al the University of Middlesex with a combined projected cost of £204,325 be￿een 2021 and 2028 First Project Title: Dellneatlng the metastatic process: the role of bone cglls. the cell envlronment and autophagy Key peoplg.. Dr Helen Robert, Dr Scoll Roberts and Daniela Palemina Martinez BACKGROUND TO THE RESEARCH PROJECT Metaslalic disease is one of the major factors affecting osteosarcoma IOS) prognosis. Survival rale of patients with melaslasis is 20Qkn lo 30Q/o compared lo up lo 800A in non-melaslatic patients. This project aims lo identify how osteosarcoma cells spread lo other tissues such a5 the lungs. Recent evidence shows that loss of a osleoclasls IIOCsl.' cells that break down bonel in the bone microonvironmenl is associated with lung melaslasis. KEY RESULTS Due lo the absence of innovative treatmen15 for osteosarcoma IOS) since the advances in chemotherapy Irealmenl in the earfy 1980s and the stagnant survival rates for patients with metaslali¢ OS, there is a pressing demand for enhanced therapeutic approaches. The Roberts lab have established a model for osteosarcoma initiation and melaslasis, alongside the idenlificalion of key largels through sequencing that rnay be able lo slop osteosarcoma in its tracks. Olh8r Oulpuls & Knowledge and Future Steps Presenlalions.. Palgrnina Martingz, D.. Roberts, S. and Roberts, H.C. 120221. Migratory bodies express markers of lumour initiating cells and may represent an early stage of osteosarcoma sarcosphere initiation and melaslasis. Journal of Bone and Mineral Research Plus. Page 12

Hannah's Willberry Wonder Pony Charity Trustees, Report Palernina Martinez. D.. Roberts. S.J and Roberts, H.C 12022). Migratory bodies express markers of lumour initiating cells and may represent an eady stsge of osteosarcoma sarcosphere initiation and metastasis. Research Students, Summer Conference. Middlesex University, London, UK JL¢ne 2022. Palernina Martinez, D., Roberts, S.J and Roberts, H.C12023.1 Osteoclasts and mesenchymal slromal cells release factors that modulate migratory body formation in highly melaslalic osteosarcoma cells. Research Sludenls, Summer Conference. Middlesex University. London, UK July 2023. Oral presentation al the Skeletal Biology Group Research Seminar- Presentslion tilled "Delineating the melaslalic process in osleosarcoma.. the role of bone cells, the cell environment and aulophagl,. Royal Veterinary College - February 2022, London. Poster presentation and poster pitch of abslra¢l enlilled 'Migralory bodies express markers of lumour initiating cells and may reprosenl an early stage of osteosarcoma sarcosphere initiation and metastasis" Bone Research Society Annual Mgeling -July 2022, Manchester. Oral presentation tilled "Bone cells modulate migratory behaviour of osleosarcoma.. implications for metastasis" Bloomsbury Centre for Skeletal Research Meeting - June 2023. London. CURRENT RESEARCH PROJECTS The second follow on project with Middlesex is tilled.. Suppress.OS: Targeting Osteoclast-Tumour Interactions to Suppress Osteosarcoma Metastasis Key people Dr Helen Roberts, Dr Song Wen BACKGROUND TO THE RESEARCH PROJECT Osteosarcoma, a form of bone cancer, becomes more challenging when it spreads. Teducing the chance of suNival. The Robert's lab hypolhesise that OS estsblishes itself in bones by inleracling with osleocl8sls, specialised Cells responsible for breaking down bone tisstje. Disruptsng this interaction allows osteosarcoma lo spread lo the lungs. In Daniella's PhD project, the Roberts lab identified 'Migralory Bodies, IMBSI as a valuable laboratory model for studying the spread of osteosarcoma. Osleoclasl factors slow down MBS, bul the drug zoledronic acid (used lo treat osleoporosisl can counlefacl this effect. The team now look to explore this further by using genetic engineering to unravel how osteosarcoma spreads. with a particular focus on potential Irealmenl targets STAT3 and MMP9. Additionally, the team plan lo examine osteosarcoma metabolism lo enhance their understanding of melaslasis. This research holds promise for refining osteosarcoma treatment slralegies, incorporating insights into osl8oclasl inleraclions, with the ultimate goal of improving outcomes for patients. Page 13

Hannah's Willberry Wonder Pony Charity Trustees, Report PRELIMINARY DATA This project is starting soon and marks our first follow-on funding project. where the teams behind our previous successfully funded projects were Invited lo apply for funding lo ensure that the most successful of these projects remain supported and continue lo grow. The Charity has also part-funded a PhD project at Kings College London with a project cost of £87,576 belmeen 2022 and October 2025 Project Title.. Drug repurposing targeting Haem oxygenase-1 IHO-11 for prevention of osteosarcoma growth and metastasis Key people.. Professor Agamemnon Grigoriadis, Dr James N Arnold. Michael Dack BACKGROUND TO THE RESEARCH PROJECT The project focuses on understanding and preventing the growth of cancer cells in osteosarcoma patients, as well as looking lo slop the spread of cancer around the body. The ability of osteosarcoma lo rlletaslasise or spread to different sites is what makes il so aggressive and therefore focusing the research on this is really important. Michael is looking al repurposing a pre-exisling drug, which is Currently used lo Ireal neonatal jaundice. to block the action of HO-1. HO-1 is a laclor which is produced by osteosarcoma patients and prevents the activation of the immune system. By 'kick-starting' the immune system into action, the project will assess if the chemotherapy drugs are able to fight the cancer and slop il from moving lo other areas of the body. KEY RESULTS Michael is now in his second year of his PhD and has been busy making progress on his project. Using a technique called Flow cytomotry, Michael has been able lo identify the key cell types within the lung that could be helping osteosarcoma spread lo this sile. Amied with this finding, Michael is now delving deeper into the mechanism of how these cells are helping the spread and how might the drug, SnMP, be working lo reactivate good immune cells lo prevent osteosarcoma metsslasis. To share his research lo potential collaborators, Michael attended EUSARC 2024 in June hosted in Le Pouligen, France and presented a 5-minule flash talk lo an international audience of sarcoma researchers. He received excellent feedback from peers. In July, Michael also attended the Bone Research Society Annual meeting in Sheffield. Here he won the Best Poster award. .In addition the Trustees are excited lo confirm that the Charity is working together with The Bone Cancer Research Trust and jointly funding a posldocloral 3 year research project of up lo £250,000 (£125,000 funded by each charilylcommencing in the 2024125 academic year with Imperial College London led by Dr Jun Ishihara. Project title.. Overcomlng osteosarcoma immunotherapy resistance by tumour-locallsed IL-12 driven anti-tumour immunlty. Key people.. Dr Jun Ishihara, Dr Koichi Sasaki, and Dr Akinobu Hamada Page 14

Hannah's Willberrywonder Pony Charity Trustees, Report BACKGROUND TO THE RESEARCH PROJECT Despite optimal management of localised osteosarcoma disease, over 500/0 of patients develop melastslic disease or recurrence. which lead lo poor suNival oul¢omes in approximately 19 months. Immunolherapies, activating immun8 cells to allack cancers. became standard therapy in many other cancer types and enablgd prolonged effects including prevention of recurrence and melaslasis. However, osteosarcoma responds poorly lo current standard immunotherapies due lo Al inaclivalion of the immune system, Bl resistsnce lo immunotherapy. and Cl difficulty in locally delivering drugs lo lumour sites. Immunotherapies can achieve long-term effects including prevention of metastasis and recurrence. There remains huge room for improvement for immunotherapy in osteosarcoma as many patients sijffer due lo lack of Irgalmenl opts'ons and recurrencelmelastasis. PRELIMINARY DATA Preliminary data from Ihe Ishihara lab has produced promising immunotherapy protein called interleukin-12 IIL-121 Ihat is known lo successfully aclivale anli-lumour immune cells against several Cancers. Despite ils strong anlitumour aclivily, IL-12 induces severe systemic loxicily in ils native form. The lab found Ihal several cancers including osteosarcoma increase collagen expression compared lo normal tissue. They successfully reduced ils toxicity, by attaching a collagen-binding domain ICBDI, which enables lumour-specific delivery of IL-12. The team hypolhesise that their newly developed lumovr-specific bioengineered immunotherapy ICBD-IL-121 can bewme a breakthrough for osteosarcoma, especially against recurrent melaslatic osteosarcoma. We have also approved funding for a project with Southampton University lolal grant £130.379 over 4 years12025-20291 Project title.. Developing a Bioengineered 3-0 Multifactorial Humanized Bone Ostgo$arcoma Model to Assess Tumour Invasiveness and Therapeutic Responso Key people.. Dr Janos Kanczler. Professor Stephen Beers, Professor Juliet Gray. Dr Yanghee Kim BACKGROUND TO THE RESEARCH PROJECT For the success of effeelive anti-bone cancer therapies. it is erucial lo understand how bone cancers such as osteosarcoma switch on. progress and develop unregulated in the bone micro-environmenl. Various cells in combination play a critical role in the progression of the disease inside of the bone slruclures. Furthermore, a soft gel- like structure (cell malrixl produced by these cells is also involved in the development of the bone cancer diseases. Southampton have previously developed a lab-based m(Idel using human bone cores and a mixture of key cells to generate a 3D model of osteosarcoma growth lo lest a cancer drug. In this study, the team will combine the unique bone gel matrix that they have previously developed with mLJltiple cells in the human bone cores lo further enhance this 3D model and understand if new therapies largeled lo tho cells in this environment or largeled lo the newly developing cell matrix can prev8nl the onset of Ihe osteosarcoma lumour. Al the same time, the team will combine the cancer therapy agents with specialised biomaterials lo help rebuild and regenerate the disease bone. •We have also approved funding for a project with Queen Mary's University total grant £122.749 over 4 years12025-20291 Page 15

Hannah's Willberry Wonder Pony Charity Trustees, Report Prolect tltle: Development of an Osteosarcoma-on.a-Chip Model to Investigate Chemoresistance and the Role of CH13L1 in Tumour Mlcroenvironment Key poople.. Dr Slefan Va￿ruggen, Dr Lucia Cottone. Associate Professor Fiona Freeman, Professor Sandra Strauss BACKGROUND TO THE PROJECT Survival of individuals with osteosarcoma, the most common primary bone can￿r which mainly affects teenagers and young adults, has not improved in the last 40 years since chemotherapy was introducod. The response lo this toxic Irealmenl is poor in neady half of the treated patients, contributing significanlly lo their lumour returning, bul the reasons for this failure have not been fully explained. Res&ar¢h into osteosarcoma has been significantly challenging due lo the rarity of this disease and lo the lack of good experimental systems lo understand the causes of chemoresislance. Moreovor. traditional drug testing using cancer cells in a dish and in small rodents have poor track records for identifying new Irealmenls, because they are loo dissimilar from the lumours. With this project we will generate an osteosarcoma 'organ-on-a-chip', a novel experimental setup that replicates the bone environment inside a bone tumour. The organ-on-a-chip will include osteosarcoma cells donated by patients and the elements of bone found in patients. We will then use the organ-on-a-ch',p lo investigate what makes cancer ￿115 resistant lo Chemotherapy. Therefore, this project will provide a new tool lo advance research and find better treatments for this paedialric cancer. We have also approved follow-on funding for a project with Kings College London, total grant £96,577 over 3 years12025-20281 Project litle.. Drug repurposing targeting Heme oxygenase-1 (HO-11 for preventlon of osteosarcoma growth and metastasis Key people.. Professor Agamemnon Grigoriadis. Professor James Arnold BACKGROUND TO THE PROJECT Osteosarcoma is a devaslaling malignancy that affects children. Melaslalic disease remains Ihe most important prognostic indicator of survival, and despite advances in adjuvant chemotherapy and limb-sparing surgery, 5-year survival is 60-70 /0, dropping lo -20°/o with melaslalic disease, and these frequencies have not improved. The team al King's have made recent progress in their ongoing HWWPC-funded project that is identifying a novel largel for OS melaslasis therapy. The enzyme, HO-1, is made by cells in the tumour immune environment. that are normally hijacked by lumour cells lo evade the immune system. The initial project uses a drug called SnMP that slops HO-1 from working, reduces OS melaslasis in animal models by r8aclivaling the immune system and enables killing of lumour cells. This project follows on from this work lo show that this HQ-1 pathway interacts with a largel in lumour cells themselves, called FGFR. Blocking FGFR in lumour cells can inhibit melaslasis but whether this affects the interaction of lumour cells with the microenvironmenl is not known. This project will establish for the first lime whether these pathways eommunicale and cooperate with each other to drive OS metastasis. Pagg 16

Hannah's Willberry Wonder Pony Charity Trustees, Report PRELIMINARY DATA PhD sludenl Michael Oack has used Flow cytomelry lo identify key cell types within the lung that could be helping osteosarcoma to spread lo this sile. Armed with this finding, Michael is now delving deeper into the mechanism of how these cells are helping Ihe Sp￿ad and how might the drug SnMP, be working lo reactivate good immune cells lo prevent osteosarcoma m&laslasis. This HWWPC follow-on fund gives the King's team the OPPOrtunily lo continue and further the work on the current HWWPC slvdenlship, which is in il's final year. PROVISION OF WISHES In respect of Willbery s Wishes, the Charity has a small team of volunteers dedicated lo helping organise and provide Ihese equeslrian-r&laled Wishes. Interest is growing and is expected lo continue to do so, as word has spread about how we can help seriously ill people and their families during the darkest of limes by giving them experiences lo look fO￿ard lo, whilst making memories for all those involved. We share details ol some of the vital Wishes we grant, bul other recipients understandably wish lo keep them private. We are immensely grateful for the continued support of so many people and organisalions in the equestrian worfd, as this is cri1￿C81 in supporting our ability lo provide Willberry s Wishes. Willbery s Wishes helps so many people, not only the Wishee bul also their families. and we always have a number of Wishes that we afe working on. Willbery's Wishes is about making memories, giving people things to look forward lo and lo forget what is happening lo them even if il is just for a little while. We hope lo help lols of people by granting many more Willberry's Wishes. Financial review The following section on Financial Review and Future Developments conslilules the Strategic Report for the purposes of the Companies Act 2006 and the Trustees confirrn that they have complied with the requirements of section 4 of the Charities Act 2011 to have due regard lo the public benefit guidance published by the Charity Commission for England and Wales. .In its ninth year of operation, the Charity genorated a surplus of £79.050 (previous year £83,630}, all of which were unrestricted funds. The Charity's main source of finance is donations, with a significant contribution also being made from the trading subsidiary. Pag8 17

Hannah's Willberry Wonder Pony Charity Trustees, Report Reserves policy The Trustees of the Charity have reviewed the Charitys reserves policy in line with the existing commitments and intended future commitments lo osteosarcoma research, Willberry's Wishes and estimates of future adminislralion costs. Al 31 Mar¢h 2025, reserves stood al £1,698.037 (£1,618,987 in the previous yearl which was substantially more than the amount required lo moel these commitments. These funds are held in low risk deposit accounts with various financial instilulions. As previously highlighted. the Charity has committed lo expenditure on fv4glve osteosarcoma research projects lo dale with a value of £1,155,480. of which £594,027 has been spent and the balance of £561,453 is committed expenditure over the next 4 years. The Charity is currently in the process of preparing for the invitstion of applications for further project funding requests from the research community, with the aim of awarding more fully funded research projects. It is anlicipaled that there will be at least 1 new project costing approximately £130.000 (project duration 4 years) committed to in each of the ngxt 5 years, total aim to be committ8d £650.000. As previously reported the Trustees aro excilod lo Confirm the conlinualion of collaboration with The Bone Cancer Research Tnjsl and expect lo offer funding of up lo £250,0001£125,000 funded by each charityl each year lo support projects focused on improving outcomes for osteosarcoma patients. Over 5 years this would arnounl lo fulure commitments of £625,000. So in summary current reserves of £1,698,037 will fund existing commitments on grant ftjnded research projects of £561,453, new grant funded project commitments of £650,000 over the next 5 years, new jointly funded projects with BCRT of £625.000, Wishes costs of £25,000 and 5 years operating costs of £240.000 1£48,000 per annuml. These future commitments will rely on the continued generation of income from donations and interest on cash balances of £100,000 per annum. In the event that suitable research projects cannot be identified then donations to other cancer research charities could be considered. Conclusion The Trustees believe that the Charity has, through Ihg kind and generous help of our supporters and volunteers, raised funds that will provide a public benefit in years lo come through the funding of bone cancer research and the provision ot Willberry s Wishes. Structure* governance and managem8nt Nature of governlng document The company is a registered charity, number 1166416, and was incorporated on 29 IAarch 2016. 11 is governed by the articles and rnemorandurn of association of that date. The company is limited by guarantee and without a share capital. All Trusle8s are members of the company and guarantee lo contribute lo the assets of the company, in the event of it being wound up, such amounts as may be required not exceeding £10. Page 18

Hannah's Willberry Wonder Pony Charity Trustees, Report Our Trustees and Management As reported in previous years, the need for employed staff has been continually under review to ensure the Charity Continues lo run efficiently and maximises its public benefit. The volume of work has continually increased over recent years, making il increasingly difficult lo operate on a volunleer-only basis. As a result on 1st March 2025 we appointed Rachel Francis as General Manager of the charity working three days per week and as a Consequen￿ she has resigned her position of trustee. This appointment was subject lo approval of the Charity Commission in line with the requirements of the charity's Articles of Association and the Charity Commission's guidance. This appointment is a real positive for the charity as Rachel has been the driv1ng force and has very much been seen as the voice of the charity, which bears her daughter's name, for many years. Her deep knowledge of the equestrian sector wher& Wishes are focussed and her empalhelic. considerate and sensitive engagement with recipients of Wishes Imany of whom are seriously or terminally illl and their families will be extremely important in Continuing lo deliver this aspect of public benefit for years to come. In addition her knowledge gained as a trustee of the s¢ienlific research environment particularly cancer l osteosarcoma and close working with other charities in the sector will as51St with the ongoing developrnenl of our research aclivilies. Al the same time as Rachel's appointment we are delighted lo report that we have appointed 2 new trustees to the charity, firstly Dr Alice Goring, who is a senior molecular scientist and completed her PhD at Soulhamplon University. Whilst studying there, she introduced us lo her supervisor, Dr Claire Clarkin, who has beèn the Chair of our Scientific Panel for the past few years. In her capacity as Trustee, Alice will provide vital knowledge of the scientific community and will help guide us with our research activities. Secondly. Matthew Clark who is Operations Director of Old Mill, an accountancy and financial advisory practice. Matt is also a survivor of osteosarcoma, which he was diagnosed with al 18 years of age, and he told us about his remarkable journey of recovery when we first mel him. Malt then SÈI himself the hugely onerous task of cycling over 1.000 miles lo all the major equestrian eventing venues with his Travelling Willberrys, raising not only a remarkable amount of money for the Charity lover £14,0001 but also increasing awareness of this hideous disease. Mall will contribute his business experience to the Charity and, Cfucially, a patient perspective lo add to all Hannah's extraordinarily powerful testimony. As a result of these changes the Charity is now run by 6 Iruslees, including Hannah's father (James Francis) and her grandmother (June Clothier). The other four Trustees are lan Pel8rs, former Financial Controller of Hanson plc, General Manager of Hanson Europe and Finance Director of Breedon Aggregates PLC, and Miles Toulson-clarke. a former Main Board Dire￿Or of Williams Lea Group and curr&nlly UK CEOIGroLJP COO of Innovation Group and District Commissioner of the Wylye Valley Pony Club, plus the newly appointed trustees, Dr Alice Goring and Matthew Clark. Each of the Trustees gives their time freely, both in their roles as Trustees and carrying out day lo day tasks in running the Charity. Day lo day activities of the Charity arg run by the newly appointed General Manager, former trustee. Rachel Francis. Each of the Trustees have oversight of particular activities on a functional basis as follows.. Alice Goring - first point of contact for research., James Francis first point of contact for Willberry s Wishes. media and communications and research,. June Clothier - trading subsidiary sales including online and at events and research,. Miles Toulson-clarke - fund raising, research and media and communications,. lan Peters - finance and legal., Matthew Clark- IT and charity operations. The charity has adopted a conflicts of intere81 policy which ensures that any remuneration and employee performance decisions do not involve any eonnecled or conflicted persons, Page 19

Hannah's Willberry Wonder Pony Charity Trustees, Report Recruitment and inductlon of new trustees Before being appointed. a potential new Iruslee is encouraged lo meet a number of limes with the existing Iruslees lo familiarise themselves with the wort( of the Charity. A newly appointed Iruslee receives guidance and informal training lo enable them to perform their duties effectively, including governance and rnanagement, an induction lo the history and Current activities of th& Charity, code of conduct and charity ethics. New trustees are provided with copies of key documents including the Charity s governing documents, minutes of recent Trustee's meetings and, once these are available, the lalesl sel of financial statements and frustees, report. Financial Instruments Objectives andpolicies The Charity's activities expose il lo a number of financial risks, principally liquidity. The Charity doBS not use derivative financial inslrumenls. Liquidity risk and interest rates The Charity s principal financial assets are bank balances and cash, trade and other receivables, and investments. The credit risk on liquid funds and derivative financial instrurnenls is limited because Ihg counterparties are banks with high credil-ralings assigned by intemational credit-raling agencies. The Charity has deliberately taken a conservative approach lo investing ils available funds during the course of the financial year which, given the current international interest environment, has generated a low rale of return. There is some residual risk to the Charity should interest rates turn negative. In order lo maintain liquidity lo ensure that suffieienl funds are available for ongoing operations and future developments. the Charity has adopted a conservative reserves policy. Pag& 20

Hannah's Willberry Wonder Pony Charity Trustees, Report Reference and Administrative Details Trustoes J S Clothier J R Francis l A Pg18rs C T M Toulson-Clark& M P Clark A L Goring 1166416 Charlty Roglstratlon Nurn￿r Company Reglstratlon Numb•r 10089069 The charlty is Incorporated In England and Wales. Manor Farm HemSngton Radstock BA3 5XX Reglltered Offlc• Ind•pendent Examlner Paul Giessler FCA Francls Clark LLP Hitchcock House Hilltop Park Devizes Road Salisbury SP3 4UF The ann¥Jal report was approved by the trustees 01 the charfty o behalf by: and slgn8d on Its l A Peters Tru51ee Page 21

Hannah's Willberry Wonder Pony Charity Trustees, Report statement of trustee8' responslbSlltle8 The trusl&&s {who are also the directors of Hannah's Willberry Wonder Pony Charity for the purpose8 of company lawl are responsiblo for preparing the Iruslees, r8POrt and the financial staternents in accordance with applicable law and United Kingdom Accounting Standards Iunilgd Klngdom Generally Acc8pl•d Accounting Practice}, including FRS 102 'The Financi81 Roporting Standard applicable in the UK and Republic of Ireland.. Company law requir85 the Iruslees to prepare financial ststemenls for each financial year. Under company law thè trustees must not approve the financlal statements unless they are sallsfled that they glve a true and fair view of the Slate of affairs of the charitable company and of the incoming re8ource8 and application of resources, including its income and expenditure. of the charitable company for that period. In preparing these financial slalements, the Iruslges are required lo= select suitsble accounting policies and apply them consislenlly., observe th8 m8thods and princSples in the Charities SORP., make ludgefflenls and estimates that are reasonable and prudent., state whether applicable accounllng stsndards, comprising FRS 102 have been followed, subject lo any material doparturos disclosed and explained in the financial statements.. and prepare the financial stslements on the going concem basis unless il is inappropriate to presume that the charitsble Gompany will conllnue Sn buslness. The Iruslees are responsible for keeping proper accounting records that can disclose wlh reasonable accuracy at any time the financial position of th8 charitable company and enable them lo ensure that the financial stslem8nts comply wlth th8 Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and henca for taking rgasonable steps for the prevenllon and detection of fraud and other irregularities. The Iruslees are responsible for thè mainlenxnce and integrity of th8 corpor8te and financial information included on the charitable compan¥s website. Legislation governing the preparation and disseminatlon of financial statements may differ from legislation In other lurfsdi¢tiong. Approved by the trustees of the charity on ....... ..... ! i. and slgned on ts behalf by.. IAPe ers Trustee Pagè 22

Hannah's Willberry Wonder Pony Charity Independent Examiner's Report to the trustees of Hannah's Willberry Wonder Pony Charity ('the Company,) l ￿port lo the charity Iruslèes on my examination of the accounts of the Company for the year ended 31 March 2025. Responsibllitles and basis of report As the charity's Iruslees of the Company land also its directors for the purposes of company lawl you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Acl 2008 I'the 2006 Act'i- Having satisfied myself that the accounts of the Company are not required lo be audited under Part 16 of the 2006 Act and are eligible for Independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 I'the 2011 Acl'l. In carrying out my exarninalion I have followed the Directions given by the Charity Commission under section 14515llbl of the 2011 Act. An independent examination does not involve gathering all the evidence that would be required in an audit and consequently does not cover all the matters that an auditor considers in giving thgir opinion on the a¢counls. The planning and conduct of an audit goes beyond the limited assurance Ihal an independent examination can provide. Consequently l express no opinion as lo whether the accounts present a 'lrue and fair. view and my report is limited lo those specific matters 581 out in tha independent examiner's slalgmenl. Independent examlnerfs statement I have completed my examination. I confirm that no matters have come lo my attention in connection with tho gxarninalion giving me cause lo b81ievo'. 1. a¢¢ounting records were not kept in respect of Hannah's Willberry Wonder Pony Charity as required by section 386 of the 2006 Act., or 2. the accounts do not accord with those records,. or 3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'lrue and fair vieW which is not a matter considered as part of an independent examination., or 4. the accounts have not been prepared in accordance with the methods and principles of the Slalement of Recommended Practice for accounting and reporting by charities lapplicable lo charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland IFRS 10211. I have no concems and have come across no other matters in connection with the examination lo which attention should be drawn in this report in order to enable a proper undersianding of the accounts lo be reached. Page 23

Hannah's Willberry Wonder Pony Charity Independent Examiner's Report to the trustees of Hannah's Willberry Wonder Pony Charity ('the Company,) Paul Giessler FCA Francis Clark LLP Hitchcock House Hilltop Park Devizes Road Salisbury SP3 4UF Dale.. 4 November 2025 Pag8 24

Hannah's Willberry Wonder Pony Charity Statement of Financial Activities for the Year Ended 31 March 2025 (Including Income and Expenditure Account and Statement of Total Recognised Gains and Losses) Unrestricted funds Total 2025 Note Income and Endowments from: Donations and legacies Investment income 107,674 47,416 107,674 47,416 Total income 155,090 155,090 Expendlture on.. Charitable activities 176,0401 176,040 Total expenditure 76,040 76,040 Nel income 79,050 79,050 Nel movement in funds 79,050 79,050 Reconciliation of funds Total funds brought fonNard 1.618,987 1.618,987 Total funds carried forward 16 1,698,037 1,698,037 Unrestrlcted funds Total 2024 Note In¢ome and Endowrnents from- Donations and legacies Investment income 123,497 33,012 123,497 33,012 Total income 156,509 156,509 Expenditure on: Charitable activities 72,8791 172,879 Total expenditure 72.879 72,879 Nel incotne 83,630 83,630 Nel movement in funds 83,630 83,630 Reconclllatlon of funds Total funds brought forward 1.535,357 1,535,357 Total funds carried forward 16 1,618,987 1,618,987 All of the charity's activities derive from continuing operations during the above two periods. The funds breakdown for 2024 is shown in note 16. The notes on pages 28 10 35 form all integial part ol these financial statements. Page 25

Hannah's Willberry Wonder Pony Charity (Registration number: 10089069) Balance Sheet as at 31 March 2025 2025 2024 Nots Flxed asSat8 Investments 10 Currènt assets Debtors Cash at b8nk and in h8nd 11 12 30.390 1.697.955 27,638 1.605,3S5 1,632.993 1.728.345 Credltors: Amounts falllng due wlthln one year Net current assets 13 30,309 14.007 1.698,036 1,618.986 Net assets 1.698.037 1.618.987 Funds ofthè charity: Unre$trf¢ted ￿n￿me funds Unreslricled funds 1.698,037 1.618.987 Totsl fvnds 16 1.698.037 1.618,987 For the finanaal year ending 31 March 2025 the charity was enlilled to exèmption from audlt under seC￿n 477 of the Companies Act 2006 relating to Small companies. DiTrctors' responsibilities= The members have not requlred th8 chadty to obtaln an audlt of Its accounts for the year quaslion In accordance with section 476,. arsd The directors acknowledge their r8sponslbllilies for complyillg with the requirements of the Act with respect to acGounling records and the preparation of accounts. Tha fina on .3.&. cia sl9lemenls on pages 25 10 35 were approved by the trustses. and aulhorised for issue .1) and signed on their behaK by.. IAPel TnJ8ts6 Th& not85 on pages 28 to 35 forrn an integral part of these financial stat8rn8nt8. Pag9 26

Hannah's Willberry Wonder Pony Charity Statement of Cash Flows for the Year Ended 31 March 2025 2025 2024 Note Cash flows from operating actiyltles Net cash income 79,050 83,630 Adjustments to cash flows from non-cash items Investment income 47.416 33,012 31,634 50.618 Working capital adlustments Increase in debtors Increasglldecreasel in creditors 12,7521 16,302 114,8011 16,7981 Nel cash flows from operating activities 45,184 29,019 Cash flows from investing activities Interest receivable and similar income 47,416 33,012 Nel increase in cash and cash equivalen15 92,800 62,031 Cash and cash equivalents al 1 April 1,605,355 1,543,324 Cash and cash equivalents al 31 March 1,697,955 1,605.355 All of the cash flows are derived from continuing operations during the above two periods. Th8 notes on pages 28 10 35 form an integral part of th8S8 linantial statements. Pag8 27

Hannah's Willberry Wonder Pony Charity Notes to the Financial Statements for the Year Ended 31 March 2025 1 Charlty status The charity Is limited by guarantee, incorporated in England and Wales, and consequently does not have share capital. Each of the trustees is liable lo contribute an amount not exceeding £10 towards the assets of the charity in the event of liquidation. The address of ils fegislered office is-. Manor Fam Heminglon Radslock BA3 5XX 2 A¢counting policies Summary of significant accounting policies and key accounting estimate$ The principal accounting policies applied in the preparation of these financial slalemenls are set out below. These policies have been consislenlly applied lo all the years presented, unless otherwise stated. Statement of compliance The financial slalemenls have been prepared in accordance with Accounting and Reporting by Charities.. Slalemenl of Recommended Practice (applicable lo charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland IFRS 10211 lissued in October 20191- (Charities SORP IFRS 10211. the Financial Reporting Standard applicable in the UK and Republic of Ireland IFRS 1021 and the Companies Act 2006. Basis of preparatlon Hannah's Willberry Wonder Pony Charity meets the dofinilion of a public benefit entity under FRS 102. Assets and liabilities are initially re¢o9nised al historical cost or transaction value unless otherwise slated in the relevant accounting policy notes. These financial statements are presented in Sterling. rounded to the nearest whole pound. Going Concern Th8 Iruslees consider that Ihere are no material uncertainties about the Charity's ability lo continue as a going concern nor any significant areas of uncertainty that affect the carrying value of assets held by the charity. Income and endowments All income is recognised once the charity has entillemenl lo the income, il is probable that the ineome will be received and the amount of the income receivable can be measured reliably. Donations and legacies Donations and legacies a￿ recognised on a receivable basis when receipt is probable and the amount can be reliably measured. Donations received through third party org8nisalions such as Just Giving are shown nel of any fees chafged by these organisalions. Page 28

Hannah's Willberry Wonder Pony Charity Notes to the Financial Statements for the Year Ended 31 March 2025 Expenditure All expenditure is recognised once there is a legal or constructive obligation lo that expenditure, it is probable settlement is required and Ihe amount can be meaSU￿d reliably. All cost5 are allocated lo the applicable expenditure heading that aggregate similar costs lo that category. Where costs cannot be directly allribuled to particular headings they have been allocated on a basis consislenl with the usfj of resources. Charitable activities Charitable expenditure comprises Ihose costs incurred by the charity in the delivery of ils activities and ServI￿S for ils beneficiaries. 11 includes both costs that can be allocated directly lo such activities and those costs of an indirect nature necessary lo support them. Grants Grants are recognised at the amount payable when the intention lo make a grant has been communicated lo the recipient and the conditions of the grant have been met. Governance costs These include the costs attributable lo the charity's compliance with conslitulional and slalulory requirements, including audit, strategic management and trustees meetings and reimbursed 8xpenses. Taxation The charity is considered lo pass the tests sel out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefor8 il meets the definition of a chaiilable company for UK Corporation tax purposes. According5y, the charity is potentially exempl from laxalion in respect of income or capital gains received within categories Covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the exlenl that such income or gains are applied exclusively to charitable purposes. Flxed asset Investments Investrnenls in subsidiaries are slated al historical cost less provisiori for any diminution in value. Cash and cash equivalents Cash and cash equivalents comprise cash on hand and call deposits, and other short-lerm highly liquid invèstments that are readily convertible lo a known amount of cash and are subject to an insignificant risk of change in value. Fund structure Unreslricled income funds are general funds that ar8 available for use al the trustees discretion in furtheranco of the objectives of the charity. Page 29

Hannah's Willberry Wonder Pony Charity Notes to the Financial Statements for the Year Ended 31 March 2025 3 Income from donations and Iogacias Unrestricted funds General Total funds Donations and legacies., General donations Donation from Ir8ding subsidiary 89,558 18.116 89,558 18,116 Total for 2025 107,674 107,674 Total for 2024 123.497 123,497 4 Investment income Unrestri¢ted funds General Total funds Interest receivable and SiTnilar income; Intere51 receivable on bank deposits 47,416 47.416 Total for 2025 47,416 47.416 Total for 2024 33,012 33,012 5 Expendlture on charitable activities Unrgstricted funds General Total funds Note Grant funding of activities Staff costs Allocal¢d support costs Governance costs 49.801 2,266 18,872 5,101 49,801 2,266 18,872 5,101 Total for 2025 76,040 76,040 Total for 2024 72,879 72,879 In addition to the expenditure analysed above. there are also govemance costs of £5,101 12024 £5,762) which relate directly to charitable activities. See note 6 for further details. Page 30

Hannah's Willberry Wonder Pony Charity Notes to the Financial Statements for the Year Ended 31 March 2025 6 Analysis of governance and support costs Charitable activities expendlture Unrestricted Total 2025 Total 2024 General Advertising, promotion and fundraising Insurance 7,889 636 4.196 7,889 636 4,196 2,000 1,227 35 Legal and professional fees Printing, postage and sl81ionary IT relaled costs Bank fees Governance costs 813 5.338 5.101 813 5,338 5,101 830 3,448 5,762 23,973 23,973 13,306 Govemance costs Unrestricted funds General Total funds Independent examiner fees Examination of the financial slal8ments Other fees paid to examiners 3,061 2,040 3,061 2.040 Total for 2025 5,101 5,101 Total for 2024 5,762 5,762 7 Trustees remuneratlon and expenses During the year the charity made the following transactions with trustees.. One trustee received reimbursed travel and subsistence of £42312024 £267). No Iruslees have re¢8ived any remuneration from the charity during the year. Rachel Francis received one month's salary in her capacity as General Manager. Her husband James Francis, a Iruslee, is deemgd to be a connected person. Page 31

Hannah's Willberry Wonder Pony Charity Notes to the Financial Statements for the Year Ended 31 March 2025 8 Staff costs The aggregate payroll costs were as follows.. 2025 Staff costs durlng the year were.. Wages and salaries Social security costs 2,083 183 2,266 The monthly average number of persons (including senior management I leadership leaml employed by the charity during the year expressed as full lime equivalents was as follows.. 2025 No One employee was employed from 1 March 2025. No employee received emoluments of rnore than £60,000 during the year. 9 Independont oxaminer's remuneration 2025 2024 Examination of the financial statements 3,061 2.915 Other fees to examlners All other services 2,040 2,847 Page 32

Hannah's Willberry Wonder Pony Charity Notes to the Financial Statements for the Year Ended 31 March 2025 10 Flxed asset investments 2025 2024 Shares in group undertakings and participating interests Details of undertakings Details of the investments in which the charity holds 200A or more of the nominal value of any class of share capital are as follows.. Country of incorporation Proportion of voting rlghts and shares held 2025 2024 Prfncipal activity Undertaking Holding Subsldlary undertaklngs Sale of merchandise and soft toys branded with Hannah's Willberry Wonder Pony The Willberry Wonder Pony Trading Company Limited Manor Farm, Heminglon, Radslock,BA3 5XX England and Wales Ordinary 100% 1 Ooyts Subsidiaries The trading subsidiary company donates ils profits lo the charity. For the period 1 April 2024 to 31 March 2025, the subsidiary's turnover was £29.477 12024 £42,000> and total expenditure was £29,47712024- £42.000). Page 33

Hannah's Willberry Wonder Pony Charity Notes to the Financial Statements for the Year Ended 31 March 2025 11 Debtors 2025 2024 Due from group undertakings 30,390 27,638 12 Cash and cash equivalents 2025 2024 Cash al bank 1,697,955 1,605,355 13 Creditors: amounts falling due within one year 2025 2024 Accruals 30,309 14,007 14 Analysis of net asset5 between funds Unrestricted funds General Total funds at 31 March 2025 Fixed asset investments Current assets Current liabilities 1.728,345 30,309 1.728,345 30,309 Total net assets 1,698,037 1,698,037 Unrestrlcted funds General Total funds at 31 March 2024 Fixed asset investments Current assets Current liabilities 1,632.993 14,007 1.632,993 114,0071 Totsl nel assets 1,618,987 1,618,987 15 Related party transactlons The charity has taken advantage of the exemption in Financial Reporting Standards 102 chapter 33 "Related Party Disclosure" and has not disclosed transactions with wholly owned group unlertakings. Donations made by the Iruslees without any conditions attached tolalled £15012024 - £4151 for the year. Page 34

Hannah's Willberry Wonder Pony Charity Notes to the Financial Statements for the Year Ended 31 March 2025 16 Funds Balance at 1 April 2024 Incoming resources Resources Balance at 31 gxpended March 2025 Unrestricted funds General 1,618,987 155.090 176,0401 1,698,037 Balance at 1 Aprll 2023 Incoming resources Resources Balance at 31 expended March 2024 Unrestricted funds General 1,535,357 156,509 72,879 1,618.987 Page 35

Hannah's Willberry Wonder Pony Charity Detailed Statement of Financial Activities for the Year Ended 31 March 2025 Total 2025 Total 2024 Donations and legacies Donation from Willberry Trading Co Other Don31ions 18,116 89,558 24,438 99,059 107,674 123,497 Investment Income Interest Received on savings alc 47,416 33,012 47,416 33.012 Charltable actlvltles Payroll Employ9r Nl Insuranc Printing Wishes costs IT related costs 12,0831 11831 16361 11,2271 141 {2,2501 18301 14.4851 18131 L j] Project costs Advertising Cornpliance inc legal Bank Fges Independent examiner's remuneralion Other fees paid lo independent examiners 145,3161 17,8891 14,1961 15,3381 13.0611 2,040 157,3231 12,0001 1351 13,4481 12,9151 2,847 76,040 {72,879 This pzge does not lom) part ol the statutory financial statements. Page 37